EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immunomodulatory Receptor ILT3/LILRB4 Protects Human Leukemic B Cells From Ferroptosis In Vitro

Roberta Drago, Rosita Del Prete, Gaia Bartolini, Virginia Anna Gazziero, Alua Kabdolova, Laura Pezzella, Giulio Caravagna, Danilo Licastro, Monica Bocchia, Alessandro Gozzetti, Anna Kabanova, Federica Nardi

European Journal of Immunology · 2026-10 · 56 (10)

DOI: 10.1002/eji.70289 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Immunoregulatory receptors determine immune cell fate by cell‐intrinsic and cell‐extrinsic mechanisms. In cancer, such feedback may enhance the selective advantage and immune evasion of tumor cells. Immunoglobulin‐like transcript 3 (ILT3 or LILRB4) is an immunomodulatory receptor ectopically expressed on the surface of chronic lymphocytic leukemia (CLL) cells, but its role in CLL remains poorly understood. Here, we identified ILT3 as a marker of proliferating CLL cells co‐expressed with immunoregulatory genes including IL‐10 , TNFRSF4 , CD276 , and IRS2 . Notably, ILT3 expression is enriched in the proliferative CXCR4 low CD5 high subset of circulating CLL cells and in tumor cells residing in the lymph node proliferative niche, linking ILT3 expression to tumor proliferative states. CRISPR/Cas9‐mediated ILT3 loss reduced survival of proliferating CLL cells and induced transcriptomic signatures of metabolic distress in an in vitro model recapitulating lymph node‐driven proliferation. Mechanistic studies revealed that ILT3 limits lipid peroxidation and protects CLL cells from ferroptosis, a form of lipid peroxidation‐driven cell death that has emerged as a cancer vulnerability. Overall, our findings identify ILT3 as a key marker of the immunoregulatory program in proliferating CLL cells and illustrate that immunomodulatory receptors contribute to the maintenance of tumor metabolic homeostasis during human CLL cell proliferation in vitro.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →